Related Experiment Video

Updated: Jul 28, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

616

Statins in hospitalized COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials

Yajuan Ren1, Guizuo Wang1, Dong Han1

  • 1Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.

Journal of Medical Virology
|May 31, 2023
PubMed

Insights

This review found that statins did not significantly reduce mortality or hospital stay for patients hospitalized with COVID-19. Routine use of statins in these patients is not recommended based on current evidence.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Statins are commonly prescribed lipid-lowering drugs with potential anti-inflammatory and immunomodulatory effects.
  • The impact of statins on outcomes for patients hospitalized with coronavirus disease-2019 (COVID-19) remains unclear.

Approach:

  • A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted.
  • Searches included major databases (PubMed, Embase, Cochrane Library, clinicaltrials.gov) without language restrictions.
  • Seven RCTs involving 1830 participants were included to assess statin efficacy in COVID-19 patients.

Key Points:

  • No statistically significant difference was observed in all-cause mortality between statin and placebo/standard care groups (RR: 0.92, 95% CI: 0.75-1.13).
  • Statins did not significantly reduce length of hospital stay (WMD: -0.21 days, 95% CI: -1.01 to 0.59 days).
  • There were no significant differences in intensive care unit (ICU) admission (RR: 1.84, 95% CI: 0.45-7.55) or mechanical ventilation rates (RR: 1.09, 95% CI: 0.70-1.70).

Conclusions:

  • Statins demonstrated no benefit in reducing mortality, ICU admission, mechanical ventilation, or length of stay in hospitalized COVID-19 patients.
  • The findings suggest that statins should likely not be routinely administered to hospitalized patients with COVID-19.
  • Further research may be needed to explore potential subgroup effects or specific indications, if any.

Keywords:
SARS coronavirusantiviral agentscoronavirus

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
717
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
15
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
12
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
12
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
17